5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

pCPA Activity increases in October 2020

November 10, 2020
-
Market Access News
-
Posted by MORSE - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): October 2020 Trends and Insights

 

October 2020 Highlights:

  • 5 products completed CADTH review
  • 7 products initiated pCPA negotiations
  • 5 negotiations were completed with an LOI
  • 0 negotiations were closed without an LOI
  • 2 files were closed without negotiation

 

Files Under pCPA Consideration:

CADTH issued 5 new recommendations in October (22 files as of October 31).

PRODUCT INDICATION SPONSOR Type REC’N* DATE
Xtandi**
(enzalutamide)
Metastatic Castration Sensitive Prostate Cancer Astellas Oncology October 8
Soliris
(eculizumab)
Myasthenia Gravis (gMG) Alexion Non-Oncology October 19
Nexplanon
(etonogestrel)
Prevention of Pregnancy Merck Non-Oncology October 20
Duobrii
(Halobetasol propionate and tazarotene)
Psoriasis, moderate to severe plaque Bausch Non-Oncology October 28
Jorveza
(budesonide)
Eosinophilic esophagitis, adults AVIR Pharma Non-Oncology October 29

* REC’N DATE = Date of CDEC Final Recommendation (non-oncology), Date Notification to Implement Issued (oncology). Note: October marks the first month that CADTH has implemented their aligned review reports, so terminology going forward in these updates will reflect this (changing from CDR to non-oncology and pCODR to non-oncology).

**File received a notification to implement and was initiated in the same month and is therefore, not included in the under-consideration count

 

 

 

Signals Decoded:

 

CADTH issued five new recommendations/notification to implement in October for a total of 22 files Under Consideration. This is the lowest Under Consideration count since April 2020 (n=20). The average time these 22 files have been under consideration continues to increase, currently at an average of 157 calendar days.  This average is largely being driven by the increasing number of files that have been under consideration for more than six months, which is at 10 as of October 31, 2020.

Negotiation Initiation:

The pCPA initiated 7 new negotiations in October (28 active negotiations as of October 31, 2020)

PRODUCT INDICATION SPONSOR CATEGORY INITIATE DATE TTI*
Aermony Respiclick
(fluticasone propionate)
Asthma Teva Canada Other October 7 N/A
Crysvita
(burosumab)
X-Linked Hypophosphatemia Ultragenyx Non-Oncology October 9 135
Erleada
(apalutamide)
Metastatic Castration Sensitive Prostate Cancer Janssen Oncology October 9 155
Nubeqa
(darolutamide)
Non-metastatic castrate resistant prostate cancer Bayer Oncology October 23 169
Entyvio SC
(vedolizumab)
Ulcerative Colitis Takeda Non-Oncology October 19 153
Vocabria and Cabenuva
(cabotegravir and rilpivirine)
HIV Infection VIIV Healthcare Non-Oncology October 22 92
Xtandi
(enzalutamide)
Metastatic Castration Sensitive Prostate Cancer Astellas Oncology October 30 22

 

 

 

Signals Decoded:

The pCPA initiated 7 negotiations in the month of October, including one re-activation for Aermony Respiclick which was previously closed in 2019. This is a significant increase to September where no files-initiated negotiations.  The volume of active files has remained relatively consistent since May with numbers between 25 and 28. This is in contrast to the trends prior to February 2020 where active negotiations were in the 32-34 range.

Completed/Closed Negotiations:

The pCPA completed 5 negotiations with a Letter of Intent (LOI) in October 2020.

PRODUCT INDICATION SPONSOR LOI DATE TTN*
Rituxan SC
(rituximab)
Chronic Lymphocytic Leukemia Hoffmann-La Roche October 14 64
Lynparza
(olaparib)
Ovarian Cancer AstraZeneca October 21 125
Kanuma
(sebelipase alfa)
Lysosomal acid lipase deficiency Alexion Pharma October 21 691
Revestive
(teduglutide)
Short Bowel Syndrome Shire Pharma October 28 250
Takhyzro
(lanadelumab)
Hereditary Angioedema Shire Pharma October 30 252

* TTN = Time to Negotiate in calendar days

 

 

Signals Decoded:

 

5 negotiations were completed during the month of October including a re-negotiation for Rituxan SC (for the treatment of CLL) which was completed relatively quickly (64 days) and Kanuma for the treatment of lysosomal acid lipase deficiency, which was the longest outstanding negotiation (691 days). The completion of Kanuma drives the average time under negotiation for currently active files down from 190 days in September to an average of 158 days as of October 31, 2020.

Not Negotiated:

The pCPA declined to negotiate 2 files in October 2020.

PRODUCT INDICATION SPONSOR DECLINE DATE TTD*
Contravenaltrexone hydrochloride and bupropion hydrochloride) Chronic Weight Management Bausch Health October 13 139
Cablivi
(caplacizumab)
Acquired thrombotic thrombocytopenic purpura Sanofi-Aventis October 23 58

* TTD = Time to Decline in calendar days

 

Signals Decoded:

 

The 2 declined negotiations, Contrave and Cablivi, both received Do Not Reimburse recommendations from CADTH. The pCPA adjudicated a total of 7 files in October, up from the previous 2 months.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
CAHR Market Access 201 Conference Update - November 2020
NEXT POST →
Numbers Steady after Limited September Outputs from pCPA and CADTH

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
pCPA Activity increases in October 2020